Although rare, status epilepticus (SE) is a potentially life-threatening condition. It affects about 50 people per 100,000 in the United States each year. In addition, about 12% of cases recur. The strongest risk factor for developing status epilepticus is a history of epilepsy, but there are also other factors that may influence the occurrence of this condition. Other risk factors include young age and genetic predisposition. In addition, exposure to certain medications and infections is also a risk factor. The age and health status of patients also increase the likelihood of experiencing this condition. In addition, fever and stroke are both potential causes. Some of the more common acute complications are cardiac arrhythmia, pulmonary edema, and relapse.
Early treatment of Status Epilepticus is crucial to preventing neurologic and systemic damage. The objective is to treat the condition quickly and to stop the seizures before they progress. For this, anti-seizure drugs must be administered intravenously. Due to the risk of adverse side effects, intravenous administration is preferable. There are several anti-seizure drugs that can be used. Each has its own advantages and disadvantages.
Regardless of the cause, rapid treatment of status epilepticus is the most important step for successful recovery. The goal of treatment is to stop the seizures before they have a chance to progress to systemic or neurologic pathology. This is best accomplished by administering anti-seizure medications intravenously. The benefits of this treatment approach include quick access to the brain and fewer adverse effects. There are several anti-seizure drugs available. All of them have their advantages and disadvantages.
However, a patient with a prolonged seizure has a chance to continue experiencing seizures for longer than five minutes. It is important to note that the duration of seizures can be difficult to diagnose and manage in some cases.
Get more pharmaceutical industry related reports here- https://www.coherentmarketinsights.com/industry/pharmaceutical
